Organon & Co. (OGN) — closed signal from December 11, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 11, 2026.
Predicted vs. what happened
What happened
Reached its target in 40 days.
The thesis — published December 11, 2025
Organon looks cheap and has good public interest, but its business results are weak, so it's a risky turnaround play rather than a reliable holding. Recent FDA approval for an oncology biosimilar is a real win, yet a major bank started a negative rating and sales are shrinking, so any recovery could be uneven and needs careful watching.
Primary drivers
- Low forward price relative to earnings makes it look like a bargain.
- Price action suggests early signs of stabilizing after declines.
- FDA approval for POHERDY boosts the oncology biosimilars lineup.
- Negative analyst rating and falling sales warn of continued risk.
How it played out
OGN: target reached in 40 days
Lyra published OGN at $7.28 on 2025-12-11 with expected growth of 22%. The thesis was a risky turnaround setup, not a reliable holding. It pointed to a low forward price relative to earnings, early price stabilization, FDA approval for POHERDY, and risks from a negative analyst rating and falling sales.
Inside the window, the stock reached the $8.88 target in 40 days. It peaked at $9.94 on 2026-01-23, with a 36.5% gain. By 2026-03-11, it had fallen to $6.48. The thesis played out on the target, but the move did not hold through the window.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.